PD-1/PD-L1 inhibitors in treatment-naïve, advanced non-small cell lung cancer patients with < 1% PD-L1 expression: a meta-analysis of randomized controlled trials-Reference-Cited by-同舟云学术

PD-1/PD-L1 inhibitors in treatment-naïve, advanced non-small cell lung cancer patients with < 1% PD-L1 expression: a meta-analysis of randomized controlled trials

Published:2022-08-19 Issue:5 Volume:149 Page:2179-2189
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Wankhede Durgesh,Hofman Paul,Grover Sandeep

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00432-022-04286-6.pdf

Reference50 articles.

1. Adam J, Le Stang N, Rouquette I et al (2018) Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer. Ann Oncol 29(4):953–958. https://doi.org/10.1093/annonc/mdy014

2. Awad MM, Gadgeel SM, Borghaei H et al (2021) Long-term overall survival from KEYNOTE-021 cohort g: pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous NSCLC. J Thorac Oncol 16(1):162–168. https://doi.org/10.1016/j.jtho.2020.09.015

3. Casarrubios M, Cruz-Bermúdez A, Nadal E et al (2021) Pretreatment tissue TCR repertoire evenness is associated with complete pathologic response in patients with NSCLC receiving neoadjuvant chemoimmunotherapy. Clin Cancer Res 27(21):5878–5890. https://doi.org/10.1158/1078-0432.CCR-21-1200

4. Chae YK, Pan A, Davis AA et al (2016) Biomarkers for PD-1/PD-L1 blockade therapy in non–small-cell lung cancer: is PD-L1 expression a good marker for patient selection? Clin Lung Cancer 17(5):350–361. https://doi.org/10.1016/j.cllc.2016.03.011

5. Chae YK, Arya A, Iams W et al (2018) Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). J Immunother Cancer 6(1):1–27

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of sarcopenia on the efficacy of PD-1 inhibitors in non-small cell lung cancer and potential strategies to overcome resistance;Frontiers in Pharmacology;2024-07-19

2. Baseline C-reactive protein predicts efficacy of the first-line immune checkpoint inhibitors plus chemotherapy in advanced lung squamous cell carcinoma: a retrospective, multicenter study;BMC Cancer;2023-12-16

3. Single-cell profiling reveals the heterogeneity of NK cells during anti-PD-1 therapy in non-small-cell lung cancer;International Immunopharmacology;2023-11

4. Dying Declaration: Musings from the Outgoing Editor;Indian Journal of Psychological Medicine;2023-08-17

5. PD-1 and PD-L1 expression in rare lung tumors;Pathology and Oncology Research;2023-05-18